降低辅助用药报销比例!17省发布新版医保目录

2018-05-20 Chriss 健识局(jianshiju01)

5月16日,安徽省人社厅发布《安徽省基本医疗保险、工伤保险和生育保险药品目录(2018年版)》,将于2018年7月1日起执行。

5月16日,安徽省人社厅发布《安徽省基本医疗保险、工伤保险和生育保险药品目录(2018年版)》,将于2018年7月1日起执行。

2018年版药品目录由凡例、西药、中成药和中药饮片四部分组成。其中,西药部分1481个、中成药部分1356个(含民族药102个),共收载药品2837个,较2010年版药品目录增加了415个,增幅约17.1%。

按照《人力资源社会保障部关于印发国家基本医疗保险、工伤保险和生育保险药品目录(2017版)的通知》要求,各省(区、市)应于2017年7月31日前,发布本地新版医保目录。据健识君统计,目前已有17省(区、市)发布相关文件。(翻至文末,查看17省发布新版医保目录详情)

而从文件看,各地的乙类药品支付标准,已较此前甲类100%,乙类80%的支付标准,有较大改变,分级分类支付已成主流。虽然同为医保乙类药品,待遇却不尽相同,可谓几家欢喜几家愁。

辅助用药

自付比例最高或至100%

安徽省《药品目录》收载的西药甲类药品402个,中成药甲类药品192个,其余为乙类药品。

就乙类药品支付标准,安徽省人社厅明确

各统筹地区,可根据基金承受能力,先设定一定的个人自付比例,再按基本医疗保险的规定给付。

对主要起辅助治疗作用或易滥用的药品,要适当加大个人自付比例,拉开与其他乙类药品的支付比例档次,并建立动态调整机制。

乙类药品的个人自付比例,由各统筹地区统一制定,并报省人力资源社会保障厅备案。

虽然,具体标准尚未公示,但按照此前安徽省发布的《安徽省基本医疗保险药品目录整合工作方案》和《安徽省基本医疗保险医疗服务项目目录》规定,在甲类、乙类之外,将《安徽省重点监控药品目录》品种设为“重点监控乙类”,建议此类药支付标准按照0.5的系数纳入政策范围可补偿费用。

而根据2017年3月福建出台的医保支付结算价,辅助用药、营养性用药的医保支付标准,从70%到50%不等。而对于中药注射剂中的非基药,一律不予报销,则使其中的辅助用药自付比例达100%。

国家谈判药品

在天津个人自付比例或最低

赫赛汀等36个国家谈判药品已于去年8月31日,纳入安徽省医保乙类目录。按当时该省人社部的要求,参保人须按国家公布的医保支付标准先行自付10%或30%,剩余的药品费用按统筹地区基本医疗保险政策由个人和基本医疗保险统筹基金按比例分担。

根据去年7月,人社部印发的《关于将36种药品纳入国家基本医疗保险、工伤保险和生育保险药品目录乙类范围的通知》,这36种谈判药品纳入了2017版国家医保目录乙类范围,并已确定相应医保支付标准。

此后(8月11日),河南省人社厅发布《关于执行国家基本医疗保险、工伤保险和生育保险药品目录(2017年版)有关问题的通知》,首个确定了国家谈判品种的个人自付比例:20%。此后,其他省(区、市)相继将其纳入医保,并确定个人先行自付比例。

而在今年5月8日,天津市人力资源和社会保障局关于2018年度医保总额管理指标全部分配情况报告中,特别提到:从医保基金预算中预留16.6亿元用于病种付费、人头付费和36种国家谈判药品按月据实支付。

此外,还需要注意,安徽省人社厅也提到:国家谈判药品的仿制药(含不同规格)同属于《药品目录》乙类药品范围,由省人力资源社会保障厅统一制定发布支付标准。

在一致性评价、医保支付方式改革持续推进的大环境下,分析人士指出,未来在以按病种付费为主的医保支付方式中,临床急需、性价比高的国家谈判药品及其仿制药将获得越来越多医保支付等方面的支持。(原标题:17省发布新版医保目录,辅助用药成了“降低报销比例”典型!)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2018824, encodeId=94f820188244f, content=<a href='/topic/show?id=7f5156068dc' target=_blank style='color:#2F92EE;'>#报销比例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56068, encryptionId=7f5156068dc, topicName=报销比例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec37461, createdName=szhvet, createdTime=Tue Jan 22 15:25:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468438, encodeId=6a42146843856, content=<a href='/topic/show?id=272833882d8' target=_blank style='color:#2F92EE;'>#医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33882, encryptionId=272833882d8, topicName=医保目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3aa6907492, createdName=juliusluan80, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486885, encodeId=45b8148688542, content=<a href='/topic/show?id=e88793e038f' target=_blank style='color:#2F92EE;'>#辅助用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93703, encryptionId=e88793e038f, topicName=辅助用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26428230653, createdName=Boyinsh, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545734, encodeId=26d21545e343c, content=<a href='/topic/show?id=8df5560640e' target=_blank style='color:#2F92EE;'>#报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56064, encryptionId=8df5560640e, topicName=报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=718013815880, createdName=ms705947299214030, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317300, encodeId=1dd431e30067, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon May 21 21:54:40 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2018824, encodeId=94f820188244f, content=<a href='/topic/show?id=7f5156068dc' target=_blank style='color:#2F92EE;'>#报销比例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56068, encryptionId=7f5156068dc, topicName=报销比例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec37461, createdName=szhvet, createdTime=Tue Jan 22 15:25:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468438, encodeId=6a42146843856, content=<a href='/topic/show?id=272833882d8' target=_blank style='color:#2F92EE;'>#医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33882, encryptionId=272833882d8, topicName=医保目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3aa6907492, createdName=juliusluan80, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486885, encodeId=45b8148688542, content=<a href='/topic/show?id=e88793e038f' target=_blank style='color:#2F92EE;'>#辅助用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93703, encryptionId=e88793e038f, topicName=辅助用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26428230653, createdName=Boyinsh, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545734, encodeId=26d21545e343c, content=<a href='/topic/show?id=8df5560640e' target=_blank style='color:#2F92EE;'>#报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56064, encryptionId=8df5560640e, topicName=报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=718013815880, createdName=ms705947299214030, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317300, encodeId=1dd431e30067, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon May 21 21:54:40 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2018824, encodeId=94f820188244f, content=<a href='/topic/show?id=7f5156068dc' target=_blank style='color:#2F92EE;'>#报销比例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56068, encryptionId=7f5156068dc, topicName=报销比例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec37461, createdName=szhvet, createdTime=Tue Jan 22 15:25:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468438, encodeId=6a42146843856, content=<a href='/topic/show?id=272833882d8' target=_blank style='color:#2F92EE;'>#医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33882, encryptionId=272833882d8, topicName=医保目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3aa6907492, createdName=juliusluan80, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486885, encodeId=45b8148688542, content=<a href='/topic/show?id=e88793e038f' target=_blank style='color:#2F92EE;'>#辅助用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93703, encryptionId=e88793e038f, topicName=辅助用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26428230653, createdName=Boyinsh, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545734, encodeId=26d21545e343c, content=<a href='/topic/show?id=8df5560640e' target=_blank style='color:#2F92EE;'>#报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56064, encryptionId=8df5560640e, topicName=报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=718013815880, createdName=ms705947299214030, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317300, encodeId=1dd431e30067, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon May 21 21:54:40 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2018824, encodeId=94f820188244f, content=<a href='/topic/show?id=7f5156068dc' target=_blank style='color:#2F92EE;'>#报销比例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56068, encryptionId=7f5156068dc, topicName=报销比例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec37461, createdName=szhvet, createdTime=Tue Jan 22 15:25:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468438, encodeId=6a42146843856, content=<a href='/topic/show?id=272833882d8' target=_blank style='color:#2F92EE;'>#医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33882, encryptionId=272833882d8, topicName=医保目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3aa6907492, createdName=juliusluan80, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486885, encodeId=45b8148688542, content=<a href='/topic/show?id=e88793e038f' target=_blank style='color:#2F92EE;'>#辅助用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93703, encryptionId=e88793e038f, topicName=辅助用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26428230653, createdName=Boyinsh, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545734, encodeId=26d21545e343c, content=<a href='/topic/show?id=8df5560640e' target=_blank style='color:#2F92EE;'>#报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56064, encryptionId=8df5560640e, topicName=报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=718013815880, createdName=ms705947299214030, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317300, encodeId=1dd431e30067, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon May 21 21:54:40 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2018824, encodeId=94f820188244f, content=<a href='/topic/show?id=7f5156068dc' target=_blank style='color:#2F92EE;'>#报销比例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56068, encryptionId=7f5156068dc, topicName=报销比例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec37461, createdName=szhvet, createdTime=Tue Jan 22 15:25:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468438, encodeId=6a42146843856, content=<a href='/topic/show?id=272833882d8' target=_blank style='color:#2F92EE;'>#医保目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33882, encryptionId=272833882d8, topicName=医保目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3aa6907492, createdName=juliusluan80, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486885, encodeId=45b8148688542, content=<a href='/topic/show?id=e88793e038f' target=_blank style='color:#2F92EE;'>#辅助用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93703, encryptionId=e88793e038f, topicName=辅助用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26428230653, createdName=Boyinsh, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545734, encodeId=26d21545e343c, content=<a href='/topic/show?id=8df5560640e' target=_blank style='color:#2F92EE;'>#报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56064, encryptionId=8df5560640e, topicName=报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=718013815880, createdName=ms705947299214030, createdTime=Tue May 22 03:25:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317300, encodeId=1dd431e30067, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon May 21 21:54:40 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-05-21 一天没事干

    很好的学习机会

    0

相关资讯

医保动手了,辅助用药遭毁灭打击

辅助用药再遭毁灭打击,医保动手了!

400多药品被重点监控

距离2018年仅剩27天——在过去的2017年,据不完全统计,截至11月21日,共计399个药品被重点监控。

神药完了!38个大品种停用

又有辅助用药被医院停用了!一度被称为“神药”的辅助用药,好日子真的到头了吗?

国家紧盯 2018医院控费来势汹汹

对于医药人而言,去年的冬天在医院控费所带来的冲击之下,显得格外寒冷。好不容易挺过了寒冬,随着国家医保局的组建,有关控费风暴是否会愈演愈烈的猜想在业内却成为了大家忧心的话题。是的,恐怕“控费”在2018年仍将卷起风云!

重点监控下的中成药和辅助用药的突围之道(上)

在2017年岁末,医药市场也像进入了冷冬,虽然偶有阳光,但也无法化解阵阵寒风给行业带来的“寒意”。这段时间,药企变相商业贿赂被罚、“神药”广告被警告、各个省市出台停用或修改各类辅助用药,行业重大事件频出。特别是辅助用药政策,很多医院面临医保的巨大压力,采取一刀切措施,停用所有的辅助用药,其中不乏过十亿的大品种。广州也重点监控67种药品,也包括喜炎平等大品种在列。另外,受到莎普爱思事件的

中药注射液不予报销,又一批“神药”被踢出医保!

对于“中国神药”、辅助用药,这边舆论还没消停,那边已有省份在行动,或准备将辅助用药踢出医保目录!